{"analyses":[{"ciLowerLimit":"0.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.32","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Response rate","paramValue":"0.17"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.","id":"OG000","title":"Gemcitabine, Docetaxel"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"every 8 weeks for approximately 8 - 48 weeks","title":"Response (Complete Response [CR] + Partial Response [PR])","type":"PRIMARY","unitOfMeasure":"participants"}